Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2007 by Rambam Health Care Campus.
Recruitment status was  Recruiting
Information provided by:
Rambam Health Care Campus Identifier:
First received: September 13, 2005
Last updated: April 10, 2007
Last verified: March 2007

The association between cancer and thrombosis is well known and the occurrence of thrombotic complications is commonly associated with poor prognosis. The aim os this study is to determine the possible value of hypercoagulable parameters as prognostic parameters in advanced non-small cell lung carcinoma (NSCLC).

Condition Intervention
Non-Small Cell Lung Carcinoma
Venous Thromboembolism
Procedure: Blood sample withdrawal

Study Type: Observational
Study Design: Primary Purpose: Screening
Time Perspective: Longitudinal
Official Title: Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

Resource links provided by NLM:

Further study details as provided by Rambam Health Care Campus:

Estimated Enrollment: 100
Study Start Date: June 2005

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of NSCLC.
  • normal serum bilirubin
  • informed concent to participate in the study

Exclusion Criteria:

  • anticoagulant therapy
  • infectious disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00192829

Contact: Galit Sarig, Ph.D +972-4-8543503
Contact: Nissim Haim, M.D

Hematology Laboratory Recruiting
Haifa, Israel
Contact: Galit Sarig, Ph.D    +972-4-8543523   
Principal Investigator: Galit Sarig, Ph.D         
Oncology Institution, Rambam Health Campus Recruiting
Haifa, Israel
Contact: Nissim Haim, M.D   
Principal Investigator: Nissim Haim, M.D         
Sponsors and Collaborators
Rambam Health Care Campus
Principal Investigator: Galit Sarig, Ph.D Rambam Health Care Campus
  More Information

Publications: Identifier: NCT00192829     History of Changes
Other Study ID Numbers: Thrombosis and cancer.CTIL
Study First Received: September 13, 2005
Last Updated: April 10, 2007
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Rambam Health Care Campus:
Lung cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Venous Thromboembolism
Venous Thrombosis
Bronchial Neoplasms
Carcinoma, Bronchogenic
Cardiovascular Diseases
Embolism and Thrombosis
Lung Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Vascular Diseases processed this record on February 27, 2015